ATE437963T1 - In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase - Google Patents

In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase

Info

Publication number
ATE437963T1
ATE437963T1 AT04723215T AT04723215T ATE437963T1 AT E437963 T1 ATE437963 T1 AT E437963T1 AT 04723215 T AT04723215 T AT 04723215T AT 04723215 T AT04723215 T AT 04723215T AT E437963 T1 ATE437963 T1 AT E437963T1
Authority
AT
Austria
Prior art keywords
cell carcinoma
vitro method
transitional cell
bladder
cancer
Prior art date
Application number
AT04723215T
Other languages
English (en)
Inventor
Martinez Antonio Martinez
Buela Laureano Simon
Cruz Simon Santa
Jimenez Maria Saenz
Vila Miguel Molina
Sanchez-Vallejo Corina Junquera
Roman Jose Javier Gomez
Gonzalez Jorge Cuevas
Original Assignee
Progenika Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma Sa filed Critical Progenika Biopharma Sa
Application granted granted Critical
Publication of ATE437963T1 publication Critical patent/ATE437963T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04723215T 2003-03-26 2004-03-25 In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase ATE437963T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200300708 2003-03-26
PCT/EP2004/003219 WO2004085676A1 (en) 2003-03-26 2004-03-25 In vitro method to detect bladder transitional cell carcinoma

Publications (1)

Publication Number Publication Date
ATE437963T1 true ATE437963T1 (de) 2009-08-15

Family

ID=33041266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723215T ATE437963T1 (de) 2003-03-26 2004-03-25 In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase

Country Status (7)

Country Link
US (1) US8124331B2 (de)
EP (1) EP1611252B1 (de)
AT (1) ATE437963T1 (de)
DE (1) DE602004022266D1 (de)
DK (1) DK1611252T3 (de)
ES (1) ES2330634T3 (de)
WO (1) WO2004085676A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US9089601B2 (en) 2006-07-10 2015-07-28 University Of Rochester Pre- and intra-operative imaging of bladder cancer
RU2321856C1 (ru) * 2006-12-12 2008-04-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ диагностики поверхностных переходноклеточных карцином мочевого пузыря
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
EP2313435A4 (de) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc An den fibroblastenwachstumsfaktorrezeptor 3 (fgfr3) bindende proteine
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
US20140030259A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
TWI606066B (zh) * 2012-09-27 2017-11-21 中外製藥股份有限公司 FGFR3 Fusion Gene and Its Targeted Medicine
KR102470456B1 (ko) * 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
EP4115891A1 (de) 2016-08-05 2023-01-11 The Research Foundation for The State University of New York Keratin 17 als biomarker für blasenkrebs
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
AU5214500A (en) * 1999-05-05 2000-11-21 Centre National De La Recherche Scientifique (C.N.R.S.) Means for detecting and treating pathologies linked to fgfr3
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Also Published As

Publication number Publication date
WO2004085676A1 (en) 2004-10-07
EP1611252A1 (de) 2006-01-04
US20070092878A1 (en) 2007-04-26
DK1611252T3 (da) 2009-11-23
US8124331B2 (en) 2012-02-28
DE602004022266D1 (de) 2009-09-10
ES2330634T3 (es) 2009-12-14
EP1611252B1 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
Sottnik et al. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases
Gu et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
Kratochvil et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
Pallanti et al. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study
EP3112476A3 (de) Verfahren, zusammensetzungen, verwendungen und kits für vitamin-d-mangel und verwandten erkrankungen
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
ATE437963T1 (de) In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE263371T1 (de) Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs
MX2011006091A (es) Inhibidores de imidazopirazina syk.
BR9914648A (pt) Processo para monitorar ação medicamentosa deinibidor de proteasoma
Suneetha Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
Bui et al. Effects of CYP3A modulators on the pharmacokinetics of naloxegol
Fujita et al. X‐ray irradiation and Rho‐kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa‐2, which exhibits mesenchymal and amoeboid motility
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
BRPI0507958A (pt) biomarcadores
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
Hatta et al. Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients
Wu et al. Glycine tomentella hayata extract and its ingredient daidzin ameliorate cyclophosphamide-induced hemorrhagic cystitis and oxidative stress through the action of antioxidation, anti-fibrosis, and anti-inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties